MedTrace Logo

Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML)

NCT00257647 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2009-02-18

No results posted yet for this study

Summary

Chronic myeloid leukemia is a serious disease which is characterized by progression from relatively quiescent stages of the disease to an aggressive phase. Although now there is highly successful medical therapy known as Gleevec (Imatinib), the treatment is not always successful and patients do develop resistance. Those patients have limited treatment options. We are developing a gene therapy model of treatment for this disease using pseudoviral particles to insert molecules of genetic material which would not allow the harmful genes causing the leukemia to function.

Conditions

  • Chronic Myeloid Leukemia

Interventions

OTHER

SV40 vectors carrying siRNA

in vitro only use of gene therapy

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Hadassah Medical Organization

    lead OTHER

Principal Investigators

  • Deborah G Rund, MD · Hadassah Medical Organization

  • Ariella Oppenheim, PhD · Hadassah Medical Organization

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Completion
2007-11-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00257647 on ClinicalTrials.gov